+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06498648

Evaluating Sequential Abemaciclib and Gemcitabine Versus Gemcitabine and Docetaxel for Advanced Soft Tissue Sarcoma

Led by National Cancer Institute (NCI) · Updated on 2026-10-21

74

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the addition of abemaciclib, a kinase inhibitor, to the chemotherapy drug gemcitabine for treating patients with advanced or metastatic soft tissue sarcoma, including leiomyosarcoma and dedifferentiated liposarcoma. This phase III trial compares the safety, best dosing, and effectiveness of this combination to the standard treatment of gemcitabine with docetaxel. The study aims to understand how these treatments affect tumor growth and patient survival. Participants in phase 1 are divided into cohorts receiving different schedules of abemaciclib taken orally and gemcitabine given intravenously, with treatment cycles repeating every 21 or 28 days for up to two years unless disease progresses or toxicity occurs. In phase 2, patients are randomized to receive either the abemaciclib and gemcitabine combination or the standard gemcitabine and docetaxel regimen, with the option to switch treatments if the disease worsens. Throughout the study, patients will undergo tumor biopsies, blood sample collections, and CT scans as part of their evaluations. During the trial, participants will have regular assessments to monitor tumor size, drug effects, and side effects using imaging, blood tests, and clinical evaluations. Researchers will measure outcomes like progression-free survival, overall survival, and response rates to treatment. After completing treatment, patients will be followed every three months for up to two years to assess long-term effects and disease status. The study includes detailed monitoring to ensure patient safety and gather information on how the treatments impact the cancer and overall health.

CONDITIONS

Brief Title

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here